Study wrapper · #51
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
Editor's note
This is a market-surveillance study, not a clinical trial, and its relevance here is regulatory rather than about efficacy. Surveying 93 Colorado websites selling compounded GLP-1 products, researchers found semaglutide advertised by nearly all and tirzepatide by many, with a small number offering combination products; BPC-157 appeared in just one. The authors specifically flag that BPC-157 has been determined by the FDA to be unsafe for compounding, and that many sites made misleading regulatory claims (implying FDA approval, or calling products 'generic'). For readers, the takeaway is about the direct-to-consumer marketplace and its claims, not about whether any of these peptides work. Semaglutide and tirzepatide are FDA-approved prescription drugs with large trial evidence; the compounded and combination versions described here fall outside that approved evidence base.
Plain-language abstract
Researchers surveyed the internet marketplace for compounded weight-loss injections in Colorado, where 'compounded' means mixed by a pharmacy rather than made by the original manufacturer. They found 93 business websites, mostly medical spas and weight-loss clinics, advertising these products across 188 locations. Almost all sold semaglutide and many sold tirzepatide; a few offered combinations with added ingredients, and just one advertised a version combined with BPC-157. The authors point out that the FDA has determined BPC-157 to be unsafe for compounding. They also found that many websites made misleading statements about the products' regulatory status, for example suggesting they were FDA-approved or 'generic' when they were not. The study is about how these products are sold and advertised, not about whether they work, and the authors call for regulatory action.